JP2024527043A - 新規多重特異性分子 - Google Patents

新規多重特異性分子 Download PDF

Info

Publication number
JP2024527043A
JP2024527043A JP2024504950A JP2024504950A JP2024527043A JP 2024527043 A JP2024527043 A JP 2024527043A JP 2024504950 A JP2024504950 A JP 2024504950A JP 2024504950 A JP2024504950 A JP 2024504950A JP 2024527043 A JP2024527043 A JP 2024527043A
Authority
JP
Japan
Prior art keywords
seq
sequence
domain
variable region
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024504950A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024527043A5 (cg-RX-API-DMAC7.html
Inventor
ルー,ホンタオ
スン,ダウェイ
ゲン,イェナン
ワン,ジン
ジャン,ハイシア
ウー,ジーハオ
ガオ,ルイ
ニウ,シャオフェン
チウ,ヤンシェン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elpiscience Biopharma Ltd
Original Assignee
Elpiscience Biopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elpiscience Biopharma Ltd filed Critical Elpiscience Biopharma Ltd
Publication of JP2024527043A publication Critical patent/JP2024527043A/ja
Publication of JP2024527043A5 publication Critical patent/JP2024527043A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
JP2024504950A 2021-07-28 2022-07-28 新規多重特異性分子 Pending JP2024527043A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2021109028 2021-07-28
CNPCT/CN2021/109028 2021-07-28
CNPCT/CN2022/103725 2022-07-04
CN2022103725 2022-07-04
PCT/US2022/074284 WO2023010098A2 (en) 2021-07-28 2022-07-28 Novel multi-specific molecules

Publications (2)

Publication Number Publication Date
JP2024527043A true JP2024527043A (ja) 2024-07-19
JP2024527043A5 JP2024527043A5 (cg-RX-API-DMAC7.html) 2025-08-04

Family

ID=85088266

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024504950A Pending JP2024527043A (ja) 2021-07-28 2022-07-28 新規多重特異性分子

Country Status (10)

Country Link
US (1) US20240336686A1 (cg-RX-API-DMAC7.html)
EP (1) EP4377357A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024527043A (cg-RX-API-DMAC7.html)
KR (1) KR20240039005A (cg-RX-API-DMAC7.html)
CN (1) CN118055946A (cg-RX-API-DMAC7.html)
AU (1) AU2022319934A1 (cg-RX-API-DMAC7.html)
CA (1) CA3226306A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024001328A (cg-RX-API-DMAC7.html)
TW (1) TW202311296A (cg-RX-API-DMAC7.html)
WO (1) WO2023010098A2 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022063272A1 (en) * 2020-09-28 2022-03-31 Elpiscience (Suzhou) Biopharma, Ltd. Novel anti-claudin18 antibodies
WO2024153193A1 (en) * 2023-01-18 2024-07-25 Elpiscience (Suzhou) Biopharma, Ltd. Bi-specific molecules targeting sirpa and claudin 18.2

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019183266A1 (en) * 2018-03-21 2019-09-26 ALX Oncology Inc. Antibodies against signal-regulatory protein alpha and methods of use
WO2021003082A1 (en) * 2019-07-03 2021-01-07 Phanes Therapeutics, Inc. Anti-claudin 18.2/anti-cd47 bispecific antibodies and uses thereof
WO2021032078A1 (en) * 2019-08-20 2021-02-25 Elpiscience (Suzhou) Biopharma, Ltd. Novel anti-sirpa antibodies
WO2021129697A1 (en) * 2019-12-24 2021-07-01 Lanova Medicines Limited Company ANTI-SIRPα MONOCLONAL ANTIBODIES AND USES THEREOF

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015138600A2 (en) * 2014-03-11 2015-09-17 The Board Of Trustees Of The Leland Stanford Junior University Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies
EP3634484A4 (en) * 2017-06-05 2022-01-12 The Council of the Queensland Institute of Medical Research A COMBINATION OF OR A BI-SPECIFIC BINDING MOLECULE TO AN IMMUNOCONTROL MOLECULE ANTAGONIST AND A RANK-L (NF-κB-LIGAND) ANTAGONIST FOR CANCER THERAPY OR PROPHYLAXIS AND USES THEREOF
MX2020013068A (es) * 2018-07-10 2021-03-02 Univ Kobe Nat Univ Corp Anticuerpo anti proteína reguladora de señales alfa sirpalfana.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019183266A1 (en) * 2018-03-21 2019-09-26 ALX Oncology Inc. Antibodies against signal-regulatory protein alpha and methods of use
WO2021003082A1 (en) * 2019-07-03 2021-01-07 Phanes Therapeutics, Inc. Anti-claudin 18.2/anti-cd47 bispecific antibodies and uses thereof
WO2021032078A1 (en) * 2019-08-20 2021-02-25 Elpiscience (Suzhou) Biopharma, Ltd. Novel anti-sirpa antibodies
WO2021129697A1 (en) * 2019-12-24 2021-07-01 Lanova Medicines Limited Company ANTI-SIRPα MONOCLONAL ANTIBODIES AND USES THEREOF

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
INT. J. BIOL. SCI., vol. 17, no. 13, JPN6026017530, 25 July 2021 (2021-07-25), pages 3281 - 3287, ISSN: 0005852221 *

Also Published As

Publication number Publication date
WO2023010098A2 (en) 2023-02-02
CA3226306A1 (en) 2023-02-02
TW202311296A (zh) 2023-03-16
WO2023010098A3 (en) 2023-04-27
US20240336686A1 (en) 2024-10-10
CN118055946A (zh) 2024-05-17
AU2022319934A1 (en) 2024-03-07
KR20240039005A (ko) 2024-03-26
MX2024001328A (es) 2024-04-01
EP4377357A2 (en) 2024-06-05
EP4377357A4 (en) 2026-05-06

Similar Documents

Publication Publication Date Title
US12226482B2 (en) Anti-SIRP-alpha antibodies and methods of use thereof
JP7091379B2 (ja) 修飾された重鎖定常領域を含む抗体
KR20200013241A (ko) 변형된 중쇄 불변 영역을 포함하는 항체
US20220106400A1 (en) Antibodies comprising modified heavy constant regions
TW202235104A (zh) 雙功能分子
JP2024531900A (ja) 新規の抗sirpa抗体
US20240336686A1 (en) Novel multi-specific molecules
AU2015367224B2 (en) IL-21 antibodies
WO2019179421A1 (en) Novel bispecific pd-1/ctla-4 antibody molecules
HK40108389A (en) Novel multi-specific molecules
HK40106257A (zh) 新型抗sirpa抗体
WO2025209593A1 (zh) 一种多特异性抗体t细胞衔接器
EA046941B1 (ru) Антитела, содержащие модифицированные константные области тяжелой цепи
EA048941B1 (ru) Антитела, содержащие модифицированные константные области тяжелой цепи

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250725

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250725

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260501

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260731